[Flunarizine--a new agent for migraine prevention. Results of a double-blind comparison with placebo].
Seventeen patients with common or classical migraine were prophylactically treated with 10 mg flunarizine daily whereas 18 patients received a placebo during a 3-month randomized double-blind study. Globally, flunarizine was significantly superior to the placebo. Only three patients felt that flunarizine had been useless and the investigator also guessed the medication code correctly in all but these three cases. Beyond a 1-month starting period the frequency of the migraine attacks became significantly lower with flunarizine than with the placebo. The mean monthly number of attacks was respectively 3.3 and 3.8 before the study and 1.4 and 3.2 during the study. The limited scale of the trial precludes a judgment as to whether one type of migraine would respond better to flunarizine than the other. Side-effects were negligible, weight gain being considered rather a secondary gain than an untoward consequence of treatment.
D001835:Body Weight / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002936:Cinnarizine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005444:Flunarizine; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D010879:Piperazines / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D010879:Piperazines; D014665:Vasodilator Agents; D002936:Cinnarizine; D005444:Flunarizine
Flunarizin--ein neues Mittel zur Migräneprophylaxe. Ergebnisse eines Doppelblindvergleichs mit Plazebo.